Maze Therapeutics, Inc. (MAZE) stock
MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$32.87−1.03 (-3.04%)
Close on Nov 17, 2026Market cap $1.83BP/E –Yield –
Maze Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Maze Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$106.54M. For fiscal 2025 it was -$111.94M, down 247.4% from the year before.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$111.94M | -247.4% |
| FY2024 | Dec 31, 2024 | $75.95M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$39.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$27.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.64M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.05M | -120.7% |
| Q1 FY2025 | Mar 31, 2025 | -$29.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$23.21M | – |
| Q2 FY2024 | Jun 30, 2024 | $145.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.44M | – |
See a number that looks wrong?